about
IMP dehydrogenase: structure, mechanism, and inhibition.Transition-state inhibitors of purine salvage and other prospective enzyme targets in malariaMizoribine Synchronized Methotrexate Therapy should be Considered when Treating Rheumatoid Arthritis Patients with an Inadequate Response to Various Combination Therapies.Mizoribine: a new approach in the treatment of renal disease.Mizoribine provides effective treatment of sequential histological change of arteritis and reduction of inflammatory cytokines and chemokines in an animal model of Kawasaki disease.Long-term post-marketing surveillance of mizoribine for the treatment of lupus nephritis: Safety and efficacy during a 3-year follow-upA four-drug combination therapy consisting of low-dose tacrolimus, low-dose mycophenolate mofetil, corticosteroids, and mizoribine in living donor renal transplantation: A randomized study.Bidirectional communication between oocytes and ovarian follicular somatic cells is required for meiotic arrest of mammalian oocytesEfficacy of mizoribine pulse therapy in patients with rheumatoid arthritis who show a reduced or insufficient response to infliximab.Mizoribine as a safe and effective combined maintenance therapy with prednisolone for anti-neutrophil cytoplasmic antibody-associated vasculitis in a hemodialysis patient.Overview of pathophysiology and treatment of human lupus nephritis.Inhibition of guanosine monophosphate synthetase by the substrate enantiomer L-XMP.mTORC1 Couples Nucleotide Synthesis to Nucleotide Demand Resulting in a Targetable Metabolic Vulnerability.Ribavirin suppresses hepatic lipogenesis through inosine monophosphate dehydrogenase inhibition: Involvement of adenosine monophosphate-activated protein kinase-related kinases and retinoid X receptor α.
P2860
Q24642299-1F729398-7C86-41EA-BD9A-246C84AD0805Q27014881-E2CEC87B-AF24-4AF4-91A8-B0492118BD84Q32182492-E39EA1A7-6291-4CE9-A04F-162BE5EDCBEAQ33568534-6A38ABFB-58C6-44B8-BDA7-B716F6C34C7FQ35617543-97EF4A4E-4E7A-44EF-B0DD-533BA24AE94DQ36165790-126D0687-F2F3-40AB-B756-414EF94FAAD9Q36912373-729436CA-0141-4D01-8983-377876757139Q37204079-7B4294F6-AD45-4C45-AD35-3EA82092F3F3Q37209761-3519EF88-F939-4D9B-90AD-25B60801E92FQ38783573-B4328579-3403-4117-9BC6-1E21DCE78BA4Q38876110-29ED69AA-E528-4988-A30D-F0A29D62CDA0Q42562410-65E8487F-E47B-46CB-9AB0-C2D50B3638BCQ47619805-274B28DA-95DD-4606-8A2F-0029E7F2E7CEQ52699072-D2F81669-E7A5-475B-856C-CABBC2EBAA2B
P2860
description
1999 nî lūn-bûn
@nan
1999 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Mizoribine and mycophenolate mofetil.
@ast
Mizoribine and mycophenolate mofetil.
@en
type
label
Mizoribine and mycophenolate mofetil.
@ast
Mizoribine and mycophenolate mofetil.
@en
prefLabel
Mizoribine and mycophenolate mofetil.
@ast
Mizoribine and mycophenolate mofetil.
@en
P1476
Mizoribine and mycophenolate mofetil.
@en
P2093
H Ishikawa
P304
P577
1999-07-01T00:00:00Z